Helmholtz Gemeinschaft


Update on biomarkers in neuromyelitis optica

[img] PDF - Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader

Item Type:Review
Title:Update on biomarkers in neuromyelitis optica
Creators Name:Melamed, E. and Levy, M. and Waters, P.J. and Sato, D.K. and Bennett, J.L. and John, G.R. and Hooper, D.C. and Saiz, A. and Bar-Or, A. and Kim, H.J. and Pandit, L. and Leite, M.I. and Asgari, N. and Kissani, N. and Hintzen, R. and Marignier, R. and Jarius, S. and Marcelletti, J. and Smith, T.J. and Yeaman, M.R. and Han, M.H.
Abstract:Neuromyelitis optica (NMO) (and NMO spectrum disorder) is an autoimmune inflammatory disease of the CNS primarily affecting spinal cord and optic nerves. Reliable and sensitive biomarkers for onset, relapse, and progression in NMO are urgently needed because of the heterogeneous clinical presentation, severity of neurologic disability following relapses, and variability of therapeutic response. Detecting aquaporin-4 (AQP4) antibodies (AQP4-IgG or NMO-IgG) in serum supports the diagnosis of seropositive NMO. However, whether AQP4-IgG levels correlate with disease activity, severity, response to therapy, or long-term outcomes is unclear. Moreover, biomarkers for patients with seronegative NMO have yet to be defined and validated. Collaborative international studies hold great promise for establishing and validating biomarkers that are useful in therapeutic trials and clinical management. In this review, we discuss known and potential biomarkers for NMO.
Source:Neurology Neuroimmunology & Neuroinflammation
Publisher:American Academy of Neurology
Page Range:e134
Date:23 July 2015
Additional Information:Friedemann Paul and Jens Wuerfel are coinvestigators of GJCF-ICC&BR.
Official Publication:https://doi.org/10.1212/NXI.0000000000000134
PubMed:View item in PubMed

Repository Staff Only: item control page


Downloads per month over past year

Open Access
MDC Library